Real-world (RW) study of outcomes for acute myeloid leukemia (AML) patients treated with glasdegib or venetoclax in US community oncology practices
This observational study supports the clinical benefit of GLAS and VEN in treating AML patients in the real-world setting.
Authors
- Jonathan Kish (ORCID: https://orcid.org/0000-0002-2824-8468)
- Prathamesh Pathak (ORCID: https://orcid.org/0009-0003-6107-4185)
- Ajeet Gajra (ORCID: https://orcid.org/0000-0002-5929-0466)
- Kristin M. Zimmerman Savill (ORCID: https://orcid.org/0000-0003-3442-7320)
- Choo Hyung Lee
- T. Alexander Russell-Smith (ORCID: https://orcid.org/0000-0003-1445-8138)
- Paul G. D'Amico (ORCID: https://orcid.org/0009-0005-4276-8821)
Institutions
- Pfizer (United States) (US)
- Flatiron Health (United States) (US)
- Individual Differences (US)
Publication Details
- Journal
- Expert Review of Hematology
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1080/17474086.2025.2492886
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00